Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | OCUL | Common Stock | Award | $0 | +55.6K | +106.38% | $0.00 | 108K | Jan 30, 2023 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | OCUL | Stock Option (Right to Buy) | Award | $0 | +167K | $0.00 | 167K | Jan 30, 2023 | Common Stock | 167K | $3.88 | Direct | F3 | |
transaction | OCUL | Stock Option (Right to Buy) | Award | $0 | +50K | $0.00 | 50K | Jan 30, 2023 | Common Stock | 50K | $3.88 | Direct | F4 |
Id | Content |
---|---|
F1 | On January 30, 2023, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service to the Company, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. |
F2 | Includes 62,223 shares of common stock of the Company underlying unvested RSUs. |
F3 | Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. |
F4 | Vests over two years, vesting 1/24 monthly beginning on the one-month anniversary of the date of grant. |